EvidenceDPreliminaryVery uncertain: animal or cell studies, or studies in people with several serious weaknesses.
We don't know yet. Young plasma hasn't been shown to reverse aging in people. Small trials changed blood markers, and none measured how long or how well people live.
Who it's for
No group has a clear benefit; research volunteers only.
What to expect
Shifts in lab markers of aging; no proven effect on health or lifespan.
Watch out for
Plasma exchange carries known procedure risks; one protocol raised some aging markers.
Figure 2. Therapeutic plasma exchange induces a coordinated biological age deceleration.
A trial of 42 healthy adults over 50 tested plasma exchange (removing old plasma) against sham treatment. Fifteen "biological age" clocks looked younger than with sham, and the effect was largest when exchange was paired with immunoglobulin infusions. The trial was small, and one analysis said no within-group change held up after correcting for the many clocks tested1Randomized trial · 2025 · 42 peopleMulti-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange.Trial Registration: Registered trial NCT06534450 on clinicaltrials. gov under the purview of the Diagnostic Investigational Review Board.Aging Cell.
A randomized trial People are assigned by chance to the treatment or a comparison, so a difference in results is likely caused by the treatment itself. of healthy blood donors found that removing plasma without young plasma or albumin gave no significant epigenetic rejuvenation. Several aging clocks rose, which suggests faster aging. The protocol didn't give conclusive evidence of benefit2Randomized trial · 2025Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial).Based on epigenetic clock parameters, it may accelerate epigenetic aging. More research into the long-term safety of this specific protocol is needed.Sci Rep. It contrasts with the first trial, and neither used a young-plasma infusion alone.
A trial of 38 older people having joint replacement gave four infusions of a young-donor plasma protein fraction or a dummy treatment (placebo A dummy treatment that looks like the real one, so people can't tell which they got.). The young fraction changed blood proteins and immune-cell signals toward less inflammation. It measured no health outcomes3Randomized trial · 2025 · 38 peopleInfusion of young donor plasma components in older patients modifies the immune and inflammatory response to surgical tissue injury: a randomized clinical trial.Reported findings provide a first proof of principle in humans that a young plasma protein fraction actively regulates inflammatory and immune responses in an elderly population. They provide a solid rationale for elucidating active principles in young plasma that may be of therapeutic benefits for a range of…J Transl Med.
A pilot study in 12 people with early memory loss replaced 16 to 26 L of plasma with young donor plasma. It was feasible, and side effects matched known plasma exchange risks. It was too small and uncontrolled to show benefit7Clinical trial · 2026Interstitial fluid rejuvenation through young-donor plasma exchange in cognitively impaired patients: a pilot safety and feasibility study.This safety and feasibility study was first registered 22 December 2023 at ClinicalTrials. gov and given the identifier NCT06234436.Geroscience.
A clinical study reported that plasma dilution moved a set of 10 protein markers toward a younger pattern4Study · 2022Old plasma dilution reduces human biological age: a clinical study.Mechanistically, the circulatory regulators of the JAK-STAT, MAPK, TGF-beta, NF-κB, and Toll-like receptor signaling pathways become more youthfully balanced through normalization of TLR4, which we define as a nodal point of this molecular rejuvenation. The significance of our findings is confirmed through big-data…Geroscience. Reviews say the strongest rejuvenation results come from animals joined by shared blood circulation or given young plasma5Review · 2025Impacts of systemic milieu on cerebrovascular and brain aging: insights from heterochronic parabiosis, blood exchange, and plasma transfer experiments.We discuss how these factors influence fundamental cellular and molecular processes of aging and impact cerebrovascular endothelial function, neurovascular coupling mechanisms, blood-brain barrier integrity, neuroinflammation, capillary density, and amyloid pathologies, with significant consequences for cognitive…Geroscience,8Review · 2026Blood as the mirror and modulator of aging: mechanistic insights and rejuvenation strategies.Collectively, these insights position blood as a central regulatory axis of aging. In this Review, we synthesize current mechanistic and translational evidence on blood-borne aging regulators to outline a molecular framework for rejuvenation biology and future therapeutic development.Exp Mol Med,9Review · 2017Therapeutic potential of systemic brain rejuvenation strategies for neurodegenerative disease.We discuss new findings that extend the beneficial effects of young blood to neurodegenerative disease models. Lastly, we explore the translational potential of blood-based interventions, highlighting current clinical trials aimed at addressing therapeutic applications for the treatment of dementia-related…F1000Res. Animal results don't establish the same effect in people.
Key studies
Study
Who
What it found
Trial, 20251Randomized trial · 2025 · 42 peopleMulti-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange.Trial Registration: Registered trial NCT06534450 on clinicaltrials. gov under the purview of the Diagnostic Investigational Review Board.Aging Cell
42 healthy adults over 50
15 age clocks looked younger than with sham
Trial, 20252Randomized trial · 2025Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial).Based on epigenetic clock parameters, it may accelerate epigenetic aging. More research into the long-term safety of this specific protocol is needed.Sci Rep
Healthy blood donors
No rejuvenation; some aging clocks rose
Trial, 20253Randomized trial · 2025 · 38 peopleInfusion of young donor plasma components in older patients modifies the immune and inflammatory response to surgical tissue injury: a randomized clinical trial.Reported findings provide a first proof of principle in humans that a young plasma protein fraction actively regulates inflammatory and immune responses in an elderly population. They provide a solid rationale for elucidating active principles in young plasma that may be of therapeutic benefits for a range of…J Transl Med
38 older surgery patients
Young plasma fraction shifted inflammation markers; no health outcomes
Pilot study, 20267Clinical trial · 2026Interstitial fluid rejuvenation through young-donor plasma exchange in cognitively impaired patients: a pilot safety and feasibility study.This safety and feasibility study was first registered 22 December 2023 at ClinicalTrials. gov and given the identifier NCT06234436.Geroscience
12 people with early memory loss
Feasible; side effects matched plasma exchange risks
Safety
In the 42-person trial, plasma exchange was judged safe, with two side effects requiring discontinuation, one tied to immunoglobulin1Randomized trial · 2025 · 42 peopleMulti-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange.Trial Registration: Registered trial NCT06534450 on clinicaltrials. gov under the purview of the Diagnostic Investigational Review Board.Aging Cell. Side effects in the memory-loss pilot were consistent with known plasma exchange risks7Clinical trial · 2026Interstitial fluid rejuvenation through young-donor plasma exchange in cognitively impaired patients: a pilot safety and feasibility study.This safety and feasibility study was first registered 22 December 2023 at ClinicalTrials. gov and given the identifier NCT06234436.Geroscience. Young plasma isn't an approved anti-aging treatment.
What we don't know
Whether any of these marker changes mean people live longer, stay stronger or think better. No trial measured frailty, healthspan or memory.
Whether the benefit comes from removing old plasma or adding young plasma, and which regimen is best.
Written by AI from the studies listed, without review by a clinician, and graded with the GRADE method. It can be wrong, so check the studies it cites. Education, not medical advice.